Pharmacokinetics and Safety of GST-HG171 Tablets in Subjects With Impaired and Normal Renal Function

Unknown 32 enrolled Fujian Akeylink Biotechnology Co., Ltd.

Non-randomizedParallel-groupOpen-labelOther

Summary

This si a single-center, non-randomized, open, parallel, single-dose trial was designed to evaluate the safety and pharmacokinetic characteristics of GST-HG171 tablets in subjects with impaired renal function.

Timeline

Start: 2023-02-10
Primary completion: 2024-02-28
Completion: 2024-03-01

Publications

Li Q, Wu M, Mao J, Zhang T, Yan W, Yan X, Li C, Zhang G, Ding Y, Mai J, Zhang H. Pharmacokinetics, safety, and dose optimization of GST-HG171 in renal impairment: insights from physiologically based pharmacokinetic modeling. Antimicrob Agents Chemother. 2026 Jul 15:e0154125. doi: 10.1128/aac.01541-25. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GST-HG171	Small molecule	150 mg	Oral
Background	Ritonavir	Other / unclassified	100 mg	—

Pharmacokinetics and Safety of GST-HG171 Tablets in Subjects With Impaired and Normal Renal Function

Summary

Timeline

Publications

Drugs

Indications